Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Akila Weerasekera has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Non-Invasive Mapping of Striosome–Matrix Imbalance in Early Psychosis

    by Akila Weerasekera, Jeff L. Waugh, Dost Öngür, Garry P. Nolan, Maria Mody, Fei Du

  • Open Access

    Deep Learning–Based Structural Brain Age Estimation in Bipolar Disorder and Schizophrenia: A Single‐Site Pilot Study

    by Akila Weerasekera, Shuqin Zhou, Chao Wang, Zhilang Qiu, Abigail Stein, Margaux Ameer, Virginie‐Anne Chouinard, Ann Shinn, Kathryn E. Lewandowski, Michael Murphy, et al.

    Accelerated brain aging has been implicated in severe mental illnesses, particularly schizophrenia (SZ) and bipolar disorder (BD). Brain–PAD, derived from structural MRI, offers a promising biomarker of neurobiological aging, but its developmental course, within‐group variability, and regional drivers remain incompletely understood. A three‐dimensional convolutional neural network (3D‐CNN) was trained exclusively on healthy controls (HC; n = 155) and then applied to independent BD ( n = 122) and SZ ( n = 161) groups. Brain–PAD was computed as predicted brain age minus chronological age. Age‐by‐group interactions, within‐group dispersion, and sensitivity analyses (e.g., piecewise regression, inverse probability weighting) were conducted. Gradient‐weighted Class Activation Mapping (Grad–CAM) was used to identify regional contributions to brain age predictions. The 3D‐CNN achieved high accuracy in HC (MAE = 3.05 years, r = 0.96), with reduced accuracy in BD (MAE = 8.86, r = 0.51) and SZ (MAE = 9.01, r = 0.48). Mean Brain–PAD was significantly elevated in BD (+4.2 ± 10.2 years) and SZ (+6.7 ± 8.7 years) relative to HC (+0.7 ± 3.5 years). Age‐by‐group analyses revealed that BD and SZ exhibited elevated Brain–PAD at younger ages, converging toward HC trajectories by midlife, followed by renewed divergence beyond age 40. This pattern was supported by piecewise and spline models showing steeper negative slopes in BD and SZ compared with HC. Variance and quantile regression indicated greater heterogeneity in BD and SZ across the Brain–PAD distribution. Grad–CAM highlighted temporal and frontal regions as central contributors across all groups; in SZ, Brain–PAD correlated positively with whole‐brain ( r = 0.23, p = 0.004), frontal ( r = 0.21, p = 0.009), and temporal ( r = 0.20, p = 0.012) activations, whereas BD showed weaker and more diffuse associations. SZ and BD exhibit elevated Brain–PAD early in adulthood with greater heterogeneity than healthy controls. Frontotemporal regions contribute prominently to brain‐age predictions, reflecting model sensitivity to age‐informative structure. These findings support Brain–PAD as a group‐level marker of apparent brain aging and motivate longitudinal study of midlife divergence.

  • Aging in Schizophrenia: Perspectives on Molecular Mechanisms and a Mini-review

    by Akila Weerasekera, Öngür Dost, Du Fei

    Background: Evidence suggests that patients with schizophrenia (SZ) experience an acceleration of the typical aging process. However, it is unclear whether this process reflects premature aging in early life or accelerated aging in later years. Nevertheless, although the timing of accelerated aging in SZ is unclear, there is a consensus that this process is characterized by dysfunctions in immune-oxidative pathway. Methods: It is a critical need to understand the mechanisms and trajectory of aging underlying SZ so we can target interventions earlier to the right mechanisms. This paper aims to review the recent literature regarding brain energy metabolism in aging with SZ, mainly focusing on the dysfunctions in immuno-oxidative pathway, limitations of studying aging in SZ, and perspective strategies for future studies. Results: Most studies reviewed in this paper point toward age-related metabolic and cognitive alterations in individuals with SZ. There are complex relationships between normative aging processes and those in SZ. However, the available data neither definitively reveal when this acceleration occurs within the life span nor attribute premature onset of aging-related changes solely to a diagnosis of SZ. Conclusions: Immuno-oxidative pathway dysregulation represents convergent processes underlying the pathophysiology of both SZ and aging, contributing to synaptic dysfunction, neuronal damage, and cognitive impairment. Further research in this domain, using an innovative accelerated longitudinal design and novel, advanced neuroimaging techniques, might open new avenues for understanding common pathophysiological mechanisms and developing therapeutic interventions targeting these interconnected pathways.


  • Open Access

    Neurometabolite Changes After Transcranial Photobiomodulation in Major Depressive Disorder: A Randomized Controlled Trial Investigating Dose-Dependent Effects

    by David R. A. Coelho, Ümit Tural, Aura Maria Hurtado Puerto, Katherine Anne Collins, Maia Beth Gersten, Zamfira Parincu, Kari Siu, Dan Vlad Iosifescu, Eva-Maria Ratai, Paolo Cassano, et al.

    Background: Transcranial photobiomodulation (t-PBM) is a promising non-invasive therapy for Major Depressive Disorder (MDD). MDD is associated with altered brain metabolism, including changes in N-acetylaspartate (NAA), choline (Cho), and creatine (Cr). This study assessed the effects of varying t-PBM doses on neurometabolite levels in the dorsolateral prefrontal cortex (dlPFC) and their correlations with clinical outcomes. Methods: In this randomized, sham-controlled, cross-over study, 33 adults with MDD received one session of t-PBM at low, medium, and high doses and a sham treatment. Proton magnetic resonance spectroscopy (1H-MRS) measured NAA, Cho, and Cr pre- and post-treatment. Clinical outcomes were assessed using the Montgomery–Åsberg Depression Rating Scale (MADRS) and the Symptoms of Depression Questionnaire (SDQ). Statistical analyses included paired t-tests or Wilcoxon signed-rank tests for neurometabolite changes, and linear mixed-effects regression models for t-PBM dose, neurometabolites, and time effects. Results: NAA levels increased significantly (7.52 ± 0.777 to 8.12 ± 1.05 mmol/L for one session; 7.36 ± 0.85 to 7.85 ± 0.68 mmol/L across all sessions); however, these changes were not associated with specific t-PBM doses or sham. No significant changes were observed for Cho and Cr levels. Positive correlations were found between Cho levels and MADRS scores (r = 0.59, p = 0.017), and negative correlations between Cr levels and SDQ scores at the medium dose (r = −0.91, p = 0.011). Conclusions: While NAA levels increased, and correlations between neurometabolites and clinical outcomes were observed, these findings do not suggest a specific effect of t-PBM. Larger randomized controlled trials with optimized dosing protocols, extended follow-up, and advanced spectroscopy are needed to clarify the neurometabolic therapeutic potential of t-PBM in MDD.


  • Cognitive Impairment in Psychotic Disorders Is Associated with Brain Reductive Stress and Impaired Energy Metabolism as Measured by 31P Magnetic Resonance Spectroscopy

    by Virginie-Anne Chouinard, Fei Du, Xi Chen, Emma Tusuzian, Boyu Ren, Jacey Anderson, Kyle Cuklanz, Wirya Feizi, Shuqin Zhou, Akila Weerasekera, et al.

    Background and Hypothesis: Convergent evidence shows the presence of brain metabolic abnormalities in psychotic disorders. This study examined brain reductive stress and energy metabolism in people with psychotic disorders with impaired or average range cognition. We hypothesized that global cognitive impairment would be associated with greater brain metabolic dysregulation. Study Design: Participants with affective and non-affective psychosis (n = 62) were administered the MATRICS Consensus Cognitive Battery (MCCB) and underwent a 31P-magnetic resonance spectroscopy scan at 4T. We used a cluster-analysis approach to identify 2 clusters of participants with and without cognitive dysfunction. We compared clusters on brain redox balance or reductive stress, measured by the ratio of nicotinamide adenine dinucleotide (NAD+) and its reduced form NADH, in addition to creatine kinase (CK) enzymatic activity and pH. Study Results: The mean (SD) age of participants was 25.1 (6.3) years. The mean NAD+/NADH ratio differed between groups, with lower NAD+/NADH ratio, suggesting more reductive stress, in the impaired cognitive cluster (t = −2.60, P = .01). There was also a significant reduction in CK activity in the impaired cognitive cluster (t = −2.19, P = .03). Intracellular pH did not differ between the 2 cluster groups (t = 1.31, P = .19). The clusters did not significantly differ on severity of mood and psychotic symptomatology or other measures of illness severity. Conclusions: Our results demonstrate that psychotic disorders with greater cognitive impairment have greater brain metabolic dysregulation, with more reductive stress and decrease in energy metabolic rate markers. This provides new evidence for the potential of emerging metabolic therapies to treat cognitive deficits in psychotic disorders.


  • Open Access

    The Case of Gnanathilaka Baddevithana: An Early Independent Investigation of One of Ian Stevenson’s Reincarnation Cases

    by James G. Matlock, Akila Weerasekera, Michael Nahm

    This paper analyzes one of the first reincarnation cases Ian Stevenson studied, in 1961, and reported in Twenty Cases Suggestive of Reincarnation. The case of Gnanathilaka Baddevithana had previously been investigated by H. S. S. Nissanka, who kept records of his interviews in writing or on tape, making this one of fewer than three dozen published cases with records produced before past-life memories were verified. Unfortunately, because the book Nissanka wrote about the case was published only in Sri Lanka, and not translated until 2001, his investigation is little known. Because Nissanka’s and Stevenson’s investigations were conducted independently, by comparing their reports, one can evaluate to what extent Stevenson’s oft-criticized practices of spending only a few days in the field and working through interpreters impacted his presentation and conclusions. These practices are shown to have led Stevenson to miss considerable detail but to have had no effect on his evaluation of Gnanathilaka’s case. This suggests that criticisms of Stevenson’s methods are misguided and that, if anything, some of the cases he reported may be phenomenologically richer and evidentially stronger than he presented them as being, rather than the reverse.


  • Dose-dependent effects of transcranial photobiomodulation on brain temperature in patients with major depressive disorder: a spectroscopy study

    by Akila Weerasekera, David Richer Araujo Coelho, Eva-Maria Ratai, Katherine Anne Collins, Aura Maria Hurtado Puerto, Luis De Taboada, Maia Beth Gersten, Julie A Clancy, Matthew J Hoptman, Molly Kennedy Irvin, et al.

    This study aimed to evaluate the dose-dependent brain temperature effects of transcranial photobiomodulation (t-PBM). Thirty adult subjects with major depressive disorder were randomized to three t-PBM sessions with different doses (low: 50 mW/cm2, medium: 300 mW/cm2, high: 850 mW/cm2) and a sham treatment. The low and medium doses were administered in continuous wave mode, while the high dose was administered in pulsed wave mode. A 3T MRI scanner was used to perform proton magnetic resonance spectroscopy (1H-MRS). A voxel with a volume of 30 × 30 × 15 mm3 was placed on the left prefrontal region. Brain temperature (°C) was derived by analyzing 1H-MRS spectrum chemical shift differences between the water (~ 4.7 ppm) and N-acetyl aspartate (NAA) (~ 2.01 ppm) peaks. After quality control of the data, the following group numbers were available for both pre- and post-temperature estimations: sham (n = 10), low (n = 11), medium (n = 10), and high (n = 8). We did not detect significant temperature differences for any t-PBM-active or sham groups post-irradiation (p-value range = 0.105 and 0.781). We also tested for potential differences in the pre-post variability of brain temperature in each group. As for t-PBM active groups, the lowest fluctuation (variance) was observed for the medium dose (σ2 = 0.29), followed by the low dose (σ2 = 0.47), and the highest fluctuation was for the high dose (σ2 = 0.67). t-PBM sham condition showed the overall lowest fluctuation (σ2 = 0.11). Our 1H-MRS thermometry results showed no significant brain temperature elevations during t-PBM administration.


  • Thalamic neurometabolite alterations in chronic low back pain: a common phenomenon across musculoskeletal pain conditions?

    by Akila Weerasekera, Paulina C. Knight, Zeynab Alshelh, Erin J. Morrissey, Minhae Kim, Yi Zhang, Vitaly Napadow, Alessandra Anzolin, Angel Torrado-Carvajal, Robert R. Edwards, et al.

    Recently, we showed that patients with knee osteoarthritis (KOA) demonstrate alterations in the thalamic concentrations of several metabolites compared with healthy controls: higher myo-inositol (mIns), lower N-acetylaspartate (NAA), and lower choline (Cho). Here, we evaluated whether these metabolite alterations are specific to KOA or could also be observed in patients with a different musculoskeletal condition, such as chronic low back pain (cLBP). Thirty-six patients with cLBP and 20 healthy controls were scanned using 1H-magnetic resonance spectroscopy (MRS) and a PRESS (Point RESolved Spectroscopy) sequence with voxel placement in the left thalamus. Compared with healthy controls, patients with cLBP demonstrated lower absolute concentrations of NAA (P = 0.0005) and Cho (P < 0.05) and higher absolute concentrations of mIns (P = 0.01) when controlling for age, as predicted by our previous work in KOA. In contrast to our KOA study, mIns levels in this population did not significantly correlate with pain measures (eg, pain severity or duration). However, exploratory analyses revealed that NAA levels in patients were negatively correlated with the severity of sleep disturbance (P < 0.01), which was higher in patients compared with healthy controls (P < 0.001). Additionally, also in patients, both Cho and mIns levels were positively correlated with age (P < 0.01 and P < 0.05, respectively). Altogether, these results suggest that thalamic metabolite changes may be common across etiologically different musculoskeletal chronic pain conditions, including cLBP and KOA, and may relate to symptoms often comorbid with chronic pain, such as sleep disturbance. The functional and clinical significance of these brain changes remains to be fully understood.


  • Open Access

    Grant Report on the Transcranial near Infrared Radiation and Cerebral Blood Flow in Depression (TRIADE) Study

    by Dan V. Iosifescu, Katherine A. Collins, Aura Hurtado-Puerto, Molly K. Irvin, Julie A. Clancy, Allison M. Sparpana, Elizabeth F. Sullivan, Zamfira Parincu, Eva-Maria Ratai, Christopher J. Funes, et al.

    We report on the rationale and design of an ongoing National Institute of Mental Health (NIMH) sponsored R61-R33 project in major depressive disorder (MDD). Current treatments for MDD have significant limitations in efficacy and side effect burden. There is a critical need for device-based treatments in MDD that are efficacious, well-tolerated, and easy to use. This project focuses on the adjunctive use of the transcranial photobiomodulation (tPBM) with near-infrared (NIR) light for the treatment of MDD. tPBM with NIR light penetrates robustly into the cerebral cortex, stimulating the mitochondrial respiratory chain, and also significantly increases cerebral blood flow (CBF). In the R61 phase, we will conduct target engagement studies to demonstrate dose-dependent effects of tPBM on the prefrontal cortex (PFC) CBF, using the increase in fMRI blood-oxygenation-level-dependent (BOLD) signal levels as our Go/No-go target engagement biomarker. In the R33 phase, we will conduct a randomized clinical trial of tPBM vs. sham in MDD to establish the target engagement and evaluate the association between changes in the biomarker (BOLD signal) and changes in clinical symptoms, while also collecting important information on antidepressant effects, safety, and tolerability. The study will be done in parallel at New York University/the Nathan Kline Institute (NYU/NKI) and at Massachusetts General Hospital (MGH). The importance of this study is threefold: 1. it targets MDD, a leading cause of disability worldwide, which lacks adequate treatments; 2. it evaluates tPBM, which has a well-established safety profile and has the potential to be safe in at-home administration; and 3. it uses fMRI BOLD changes as a target engagement biomarker. If effects are confirmed, the present study will both support short-term clinical development of an easy to scale device for the treatment of MDD, while also validating a biomarker for the development of future, novel modulation strategies.